THE IMPACT OF TRUS IN DETECTION OF PROSTATE CANCER IN GEZIRA, SUDAN
Abstract
Introduction: Prostate cancer (P ca) is the most commonly diagnosed visceral cancer worldwide. It is the second cause of cancer death in men.
Objective: To study the impact of introducing transrectal ultrasound (TRUS)-guided biopsy in detection of Prostate cancer in Central Sudan.
Methods: This was a retrospective hospital based study. A review was done for data of prostate cancer patients treated in the Institute of Nuclear Medicine and Oncology & Gezira Hospital of Renal Diseases & Surgery (GHRD&S), Wad Medani, Sudan during the years 2002-2007. Comparison was done between the data available before and after introduction of trans rectal ultrasound biopsy, TRUS in 2005.
Results: Prostate cancer cases were contributing for only 8% of all cancers during the time period before TRUS introduction. During the year 2007 the figure increased to 14%. The leading cancer in males now is the P ca. previously it was the third registered cancer before TRUS was introduced. The detection of new cases per year increased dramatically after the introduction of TRUS service.
Conclusion and recommendation: Prostate cancer was found to be the most common cancer in Sudanese males. TRUS guided biopsy contributed significantly in early detection of prostate cancer in this region. Distribution of this facility with adequate training of the staff optimizes a proper and early detection of prostate cancer.
References
2- Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani, Frédéric Staerman, Claude C Schulman. What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses- 2006. European Urology; 2007; 6(4):404-412
3- Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000 Jan 1;85(1):60-7.
4- Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control; 2006; 13(3):158-68.
5- Nicolas Mottet, Jack A. Schalken, Axel Heidenreich, Patrick J. Bastian, Jacques Irani, Laurent Salomon, Michel Soulié. Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. European Urology; 2008; 7 (6): 460-476.
6- Melia J. Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales. BJU international; 2005; 95: 4-15.
7- Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol; 2004; 172(4 Pt 1):1297-301.
8- Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, Reuther AM, Klein EA. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol; 2004; 22(4): 300-306.
9- Stamey TA. Making the most out of six systematic sextant biopsies. Urology; 1995; 45(1): 2-12.
10- Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol; 2007; 52(5):1309-22.
11- Terris MK, Hammerer PG, Nickas ME. Comparison of ultrasound imaging in patients undergoing transperineal and transrectal prostate ultrasound. Urology; 1998; 52(6):1070-2.
12- Pelzer AE, Bektic J, Berger AP, Halpern EJ, Koppelstätter F, Klauser A, Rehder P, Horninger W, Bartsch G, Frauscher F. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. Eur Urol; 2005; 48(6):916-21.
13- Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol; 1989; 142(1): 71-74.
14- Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol; 1998; 160(6 1): 2111-2114.
15- Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol; 1997; 157(1): 199-202.
16- Fatima A, Elimam M, Khalid E, Nasr Eldin M, Omran M, Eltom K. The utility of free and total prostate specific antigen and prostatic acid phosphatase
as tumor markers in Sudanese patients with prostate enlargement. Journal of the Arab Board of Medical Specialization 2005; 7(3): 255-59.
17- Axel H. Gunnar A, Michel C B. et al. EAU Guidelines on prostate cancer European Urology; 2008; 53: 68-80.
18- Yoar B Simon E, Fowzia I. et al. The risk of Pca amongst black men in the U.K, European Urology; 2008; 53: 99-105.
19- Parkin Dm, Ferlay J, Hamdi cherif M. et al. Cancer in Africa, epidemiology & prevalence. 1st ed. Lyon (France). LARC scientific publication No. 153:2003.
20- AUS G, Abbou CC, Bolla M, et al. EAU Guidelines in Pca. Euroopean Urology; 2005; 48: 546-51.
21- Hamad HMA. Cancer initiative in Sudan. Annals of Oncol; 2006; 17 (suppl 8): viii32-36.
22- Gupta NP, Ansari MS, Dass SC. TRUS guided biopsy for detecting early prostate cancer: An Indian experience. India J Cancer; 2005; 42: 151-154.
23- Terris MK, Freiha FS, McNeal JE, Stamey TA (1991) Efficiacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 146:78.
Norberg M, Egevad L,Holmberg L, Sparen P, Norlen B J, Busch C (1997) The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50:562–566
